Mind-NRG, a Geneva, Switzerland-based company focusing on developing neuregulins to treat neurodegenerative diseases, closed its €6m (approximately $8m) Series B financing.
Backers included new investor LRM and existing investor Index Ventures. Following the investment, Debora Dumont, Head of Health & Care at LRM will join the company’s board of directors.
Created in 2010, Mind-NRG is investigating the use of neuregulins in treating a variety of neurological and psychiatric disorders. In particular, it is developing NRG-101 to treat the early-stages of neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, as well as schizophrenia.
The company plans to use the funding to continue to develop NRG-101’s neuroprotective effect in Parkinson’s disease, with the aim of advancing the compound to proof-of-concept studies in patients.
FinSMEs
04/09/2013